Calcium levels decreased less with each subsequent denosumab dose among individuals with osteoporosis and advanced chronic kidney disease.

Median CRP level was 2.0 mg/mL at eGFR ... CKD progression rate doubled from 11.7 to 23.6 per 1000 person-years from the lowest to highest CRP category. AKI risk significantly increased 18%, 34% ...

"UTIs resulting in a negative eGFR change may have long ... of recurrences by 50% (HR 0.50, 95% CI 0.34 to 0.74) versus placebo, the occurrence of renal scarring did not differ significantly ...

Renal gluconeogenesis ... 17.8 PPG (mg/dl):/DP20 mg: −41.9/DP10 mg: −34.3/PL: 18.7 Body weight (kg):/DP20 mg: −4.3/DP10 mg: −4.5/PL: −1.9 Urinary glucose excretion (g/24 h):/DP20 ...

Finerenone also reduced urine albumin-creatinine ratio (UACR) by 30% (95% CI 25-34) over 6 months ... reduce the risk of ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...

Janux Therapeutics (NASDAQ:JANX – Get Free Report)‘s stock had its “outperform” rating reissued by equities research analysts at William Blair in a research report issued to clients and investors on ...

GFR is also dependent on the vasodilator effects of prostaglandins ... associated with an increase in the risk of subsequent admission for heart failure.34 Renal function often does not to return to ...

Pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved: Renal outcomes (profound and sustained decreases in eGFR or renal replacement therapy ... (7.5 vs 5.6 events per 100 patient-years; HR, 1.34; ...

P<0.001), 8.66% patients at high CKD severity (SHR quintile 1 to 5 = 8.34%: 9.15%: 6.40%: 8.72%: 10.71%, P<0.001), and 5.08% patients at very high CKD severity (SHR quintile 1 to 5 = 5.81%: 3.33%: ...